Filing Flows › Heron Therapeutics (HRTX) › R&D spending
Heron Therapeutics (HRTX) R&D spending by quarter
Heron Therapeutics' R&D spending was $2.7M in Q2 2026 (second quarter 2026), +13% from Q1 2026. Over the last 7 quarters it ranged from $2.3M (Q1 2025) to $3.7M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.7M | +13% | -8% |
| Q1 2026 | $2.4M | -36% | +5% |
| Q4 2025 | $3.7M | +8% | +18% |
| Q3 2025 | $3.5M | +18% | — |
| Q2 2025 | $2.9M | +29% | — |
| Q1 2025 | $2.3M | -28% | — |
| Q4 2024 | $3.2M | — | — |
Q2 2026 at a glance
Heron Therapeutics, Q2 2026: revenue $37.7M (+1% year over year), operating margin -5.4%, net loss $5.5M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Heron Therapeutics' R&D spending?
Heron Therapeutics' R&D spending was $2.7M in Q2 2026 (second quarter 2026), +13% from Q1 2026.
How has Heron Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $2.3M (Q1 2025) to $3.7M (Q4 2025).